7,619 Shares in ANI Pharmaceuticals, Inc. $ANIP Acquired by Ellsworth Advisors LLC

Ellsworth Advisors LLC bought a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 7,619 shares of the specialty pharmaceutical company’s stock, valued at approximately $650,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ANIP. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at $28,000. Hantz Financial Services Inc. increased its position in shares of ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after purchasing an additional 237 shares during the last quarter. Newbridge Financial Services Group Inc. raised its holdings in ANI Pharmaceuticals by 200.0% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after buying an additional 400 shares during the period. State of Wyoming purchased a new stake in ANI Pharmaceuticals in the 2nd quarter valued at about $50,000. Finally, CWM LLC lifted its position in ANI Pharmaceuticals by 159.1% in the third quarter. CWM LLC now owns 798 shares of the specialty pharmaceutical company’s stock valued at $73,000 after buying an additional 490 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Down 2.3%

Shares of NASDAQ:ANIP opened at $74.21 on Friday. The firm has a market capitalization of $1.66 billion, a PE ratio of 22.09 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 1 year low of $56.71 and a 1 year high of $99.50. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19. The firm’s 50-day moving average is $76.78 and its two-hundred day moving average is $83.32.

Analyst Ratings Changes

A number of brokerages have weighed in on ANIP. Barclays began coverage on shares of ANI Pharmaceuticals in a research report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target for the company. Guggenheim upped their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. Finally, Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,312 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $75.50, for a total value of $552,056.00. Following the completion of the transaction, the chief financial officer owned 185,543 shares of the company’s stock, valued at $14,008,496.50. This trade represents a 3.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Meredith Cook sold 500 shares of the company’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $72.62, for a total value of $36,310.00. Following the sale, the vice president directly owned 79,390 shares in the company, valued at $5,765,301.80. This represents a 0.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 27,860 shares of company stock worth $2,114,771 over the last 90 days. 11.10% of the stock is currently owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.